Stocktoria
ARS Pharmaceuticals, Inc. SPRY
ARS Pharmaceuticals, Inc. (SPRY) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $84.3M at a -203.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.75 |
| Retained earnings / assets | -0.899 |
| EBIT / assets | -0.548 |
| Equity / liabilities | 0.535 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
| CYTK | CYTOKINETICS INC | 3/9 | -7.91 | — | +376.6% |
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
FAQ
Is SPRY financially healthy?
ARS Pharmaceuticals, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SPRY pay a dividend?
No, ARS Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is SPRY?
In FY2025, ARS Pharmaceuticals, Inc. had a net margin of -203.3% and a return on equity of -149.9%.
What is the analyst price target for SPRY?
The average Wall-Street price target for ARS Pharmaceuticals, Inc. is $29.25, about 383.5% above the recent price, from 4 analysts (consensus: strong buy).
Is SPRY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ARS Pharmaceuticals, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.